Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 35

1.

Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.

du Bois A, Kristensen G, Ray-Coquard I, Reuss A, Pignata S, Colombo N, Denison U, Vergote I, Del Campo JM, Ottevanger P, Heubner M, Minarik T, Sevin E, de Gregorio N, Bidziński M, Pfisterer J, Malander S, Hilpert F, Mirza MR, Scambia G, Meier W, Nicoletto MO, Bjørge L, Lortholary A, Sailer MO, Merger M, Harter P; AGO Study Group led Gynecologic Cancer Intergroup/European Network of Gynaecologic Oncology Trials Groups Intergroup Consortium.

Lancet Oncol. 2016 Jan;17(1):78-89. doi: 10.1016/S1470-2045(15)00366-6. Epub 2015 Nov 16.

PMID:
26590673
2.

Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial.

Lee AY, Kamphuisen PW, Meyer G, Bauersachs R, Janas MS, Jarner MF, Khorana AA; CATCH Investigators.

JAMA. 2015 Aug 18;314(7):677-86. doi: 10.1001/jama.2015.9243.

PMID:
26284719
3.

A novel diagnostic index combining HE4, CA125 and age may improve triage of women with suspected ovarian cancer - An international multicenter study in women with an ovarian mass.

Karlsen MA, Høgdall EV, Christensen IJ, Borgfeldt C, Kalapotharakos G, Zdrazilova-Dubska L, Chovanec J, Lok CA, Stiekema A, Mutz-Dehbalaie I, Rosenthal AN, Moore EK, Schodin BA, Sumpaico WW, Sundfeldt K, Kristjansdottir B, Zapardiel I, Høgdall CK.

Gynecol Oncol. 2015 Sep;138(3):640-6. doi: 10.1016/j.ygyno.2015.06.021. Epub 2015 Jun 16.

PMID:
26086566
4.

Prevention of irinotecan induced diarrhea by probiotics: A randomized double blind, placebo controlled pilot study.

Mego M, Chovanec J, Vochyanova-Andrezalova I, Konkolovsky P, Mikulova M, Reckova M, Miskovska V, Bystricky B, Beniak J, Medvecova L, Lagin A, Svetlovska D, Spanik S, Zajac V, Mardiak J, Drgona L.

Complement Ther Med. 2015 Jun;23(3):356-62. doi: 10.1016/j.ctim.2015.03.008. Epub 2015 Apr 4.

PMID:
26051570
5.

[Preinvasive lesions in gynaecology -  endometrium].

Feranec R, Mouková L, Chovanec J.

Klin Onkol. 2013;26 Suppl:S52-3. Review. Czech.

PMID:
24325166
6.

[Preinvasive lesions in gynaecology - uterine cervix].

Mouková L, Feranec R, Chovanec J.

Klin Onkol. 2013;26 Suppl:S49-51. Review. Czech.

PMID:
24325165
7.

[Preinvasive lesions in gynaecology -  vagina].

Feranec R, Mouková L, Chovanec J.

Klin Onkol. 2013;26 Suppl:S47-8. Review. Czech.

PMID:
24325164
8.

[Preinvasive lesions in gynecology -  vulva].

Chovanec J, Mouková L, Feranec R.

Klin Onkol. 2013;26 Suppl:S44-6. Review. Czech.

PMID:
24325163
9.

[Prognostic factors for cervical cancer].

Mouková L, Nenutil R, Fabian P, Chovanec J.

Klin Onkol. 2013;26(2):83-90. Review. Czech.

PMID:
23718666
10.

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.

Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R; Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group.

Lancet. 2013 Mar 9;381(9869):805-16. Erratum in: Lancet. 2013 Mar 9;381(9869):804.

11.

[Another positive study of ovarian carcinoma].

Chovanec J.

Klin Onkol. 2012;25(5):386. Czech. No abstract available.

PMID:
23102202
12.

A comparison of dequalinium chloride vaginal tablets (Fluomizin®) and clindamycin vaginal cream in the treatment of bacterial vaginosis: a single-blind, randomized clinical trial of efficacy and safety.

Weissenbacher ER, Donders G, Unzeitig V, Martinez de Tejada B, Gerber S, Halaška M, Špaček J; Fluomizin Study Group.

Gynecol Obstet Invest. 2012;73(1):8-15. doi: 10.1159/000332398. Epub 2011 Dec 24.

13.

[Guideline for treatment of gynaecological malignant tumours 2010---endometrial carcinoma].

Svoboda B, Líbalová P, Kubecová M, Rob L, Freitag P, Pilka RS, Chovanec J, Tikovský K, Vernerová Z, Oncogynecologic Section of the Czech Gynecologic and Obstetric Society.

Ceska Gynekol. 2011 Jun;76(3):208-15. Czech.

PMID:
21838152
14.

Relationship of resistin levels with endometrial cancer risk.

Hlavna M, Kohut L, Lipkova J, Bienertova-Vasku J, Dostalova Z, Chovanec J, Vasku A.

Neoplasma. 2011;58(2):124-8.

PMID:
21275461
15.

A common variation in the cannabinoid 1 receptor (CNR1) gene is associated with pre-eclampsia in the Central European population.

Bienertova-Vasku J, Bienert P, Dostalova Z, Chovanec J, Vasku A, Vasku V.

Eur J Obstet Gynecol Reprod Biol. 2011 Mar;155(1):19-22. doi: 10.1016/j.ejogrb.2010.11.004. Epub 2010 Dec 3.

PMID:
21129839
16.

[Level of CA125 and hemoglobin as prognostic factors ovarian cancer].

Chovanec J, Bienertová-Vasků J, Dostálová Z, Minár L.

Ceska Gynekol. 2009 Aug;74(4):269-73. Czech.

PMID:
20564980
17.

[Vaccination against human papillomavirus in the Czech Republic].

Mouková L, Feranec R, Chovanec J.

Klin Onkol. 2010;23(2):125-6. Czech. No abstract available.

PMID:
20465093
18.

[Sentinel lymph node identification using hysteroscopy in patients with endometrial cancer].

Feranec R, Mouková L, Stanícek J, Stefániková L, Chovanec J.

Klin Onkol. 2010;23(2):92-8. Czech.

PMID:
20465087
19.

Leptin--2548 g/A polymorphism in endometrial cancer.

Chovanec J, Bienertová-Vasků JA, Dostálová Z.

Klin Onkol. 2009;22(5):223-7.

PMID:
19886360
20.

Gemcitabine and carboplatin treatment in patients with relapsing ovarian cancer.

Sufliarsky J, Chovanec J, Svetlovska D, Minarik T, Packan T, Kroslakova D, Lalabova R, Helpianska L, Horvathova D, Sevcik L, Spacek J, Laluha A, Tkacova V, Malec V, Rakicka G, Magdin D, Jancokova I, Dorr A, Stresko M, Habetinek V, Koza I.

Neoplasma. 2009;56(4):291-7.

PMID:
19473054
Items per page

Supplemental Content

Loading ...
Write to the Help Desk